Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
NBIX News
Neurocrine Biosciences ((NBIX)) has held its Q3 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of T...
Are you on the fence about what to do with Neurocrine Biosciences stock? If you have been scanning your watchlist lately, you've probably noticed NBIX holding r...
Neurocrine Biosciences ((NBIX)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50...
Analyst ratings
87%
of 30 ratingsMore NBIX News
Needham raised the firm’s price target on Neurocrine (NBIX) to $184 from $170 and keeps a Buy rating on the shares. The company reported a strong Q3, with EPS t...
Analyst Ami Fadia of Needham maintained a Buy rating on Neurocrine, boosting the price target to $184.00. Elevate Your Investing Strategy: Take advantage of Tip...
The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks tradin...
Home Investing Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock Investing Neurocrine Biosciences Beats Estimates But Wall Street Puni...
Late Tuesday, Neurocrine Biosciences (NBIX) reported adjusted earnings of $2.17 per share on $790 million in third-quarter sales. In response, Neurocrine stock...
Neurocrine Biosciences (NBIX) recently shared updated data from its Phase 3 KINECT 4 study, highlighting meaningful improvements for tardive dyskinesia patients...